AD

Award Number: DAMD17-02-1-0561

TITLE: Endothelial Cell-Targeted Adenoviral Vector for Suppressing Breast Tumors

PRINCIPAL INVESTIGATOR: Shuang Huang, Ph.D.

CONTRACTING ORGANIZATION: The Scripps Research Institute La Jolla, California 92037

REPORT DATE: April 2003

TYPE OF REPORT: Annual

- PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
- DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030904 083

REPORT DOCUMENTATION PAGE Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching exist reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestion information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Artington, VA 22202-4302, and to the Office of Management and Budget, Pape			Form Approved OMB No. 074-0188	
			sting data sources, gathering a	nd maintaining the data needed, and completin
Information Operations and Reports, 1215 Jefferson Da 1. AGENCY USE ONLY (Leave blank)	vis Highway, Suite 1204, Arlington, VA 22202-4302, and to t 2. REPORT DATE	the Office of Management and Budget, Pap 3. REPORT TYPE AND I	erwork Reduction Project (070	4-0188), Washington, DC 20503
	April 2003	Annual (1 Apr	[.] 02 - 31 Ma	r 03)
4. TITLE AND SUBTITLE		The share from	5. FUNDING NU	
	Targeted Adenoviral	. vector for		02-1-0561
Suppressing Breas	LIUMOIS			
6. AUTHOR(S):			_	
Shuang Huang, Ph.	D.			
7. PERFORMING ORGANIZATION NA	ME(S) AND ADDRESS(ES)		8. PERFORMING REPORT NUM	
The Scripps Research Institute			ALFORT NOMBER	
La Jolla, Califor				
	·			
E-Mail: shuang@scripps.edu				
9. SPONSORING / MONITORING AGI	ENCY NAME(S) AND ADDRESS(ES)		10, SPONSORING / MONITORING	
U.S. Army Medical Research and Materiel Command			AGENCY REPORT NUMBER	
Fort Detrick, Maryland 21702				
•				
11. SUPPLEMENTARY NOTES				
				T
12a. DISTRIBUTION / AVAILABILITY Approved for Public I		nlimited		12b. DISTRIBUTION CODE
	STATEMENT Release; Distribution U	nlimited		12b. DISTRIBUTION CODE
		Inlimited		12b. DISTRIBUTION CODE
		nlimited		12b. DISTRIBUTION CODE
Approved for Public H			ormation)	12b. DISTRIBUTION CODE
Approved for Public H 13. Abstract (Maximum 200 Wor	Release; Distribution U rds) (abstract should contain no prop	prietary or confidential info		
Approved for Public I 13. Abstract (Maximum 200 Woo Angiogenesis is essential for	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of	orietary or confidential info solid tumors includin	g breast cancer.	In vitro and in vivo
Approved for Public I 13. Abstract (Maximum 200 Wow Angiogenesis is essential for experimental models clearly	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing	prietary or confidential info solid tumors includin angiogenesis leads to	g breast cancer. tumor suppress	In vitro and in vivo sion. The overall goal o
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap	prietary or confidential info solid tumors includin angiogenesis leads to pproach for suppressi	g breast cancer. tumor suppress ng angiogenesis	In vitro and in vivo sion. The overall goal o s. In the first year of the
Approved for Public I 13. Abstract (Maximum 200 Wol Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the em	orietary or confidential info solid tumors includin, angiogenesis leads to pproach for suppressi adothelial cell-targeted	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated f
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en relial cell-specific peptide sequ	solid tumors includin angiogenesis leads to pproach for suppressi idothelial cell-targeted ences into adenovirus	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve s capsid fiber se	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated f quence and the modifie
Approved for Public I 13. Abstract (Maximum 200 Won Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β-galac	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- nelial cell-specific peptide seque ctosidase-containing adenovirus	solid tumors including angiogenesis leads to pproach for suppressing adothelial cell-targeted ences into adenovirus s with a helper-cell st	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve s capsid fiber se rategy. We exan	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated i quence and the modifie mined the infectivity ar
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β-galac specificity on human microw	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide sequ ctosidase-containing adenovirus vascular endothelial cells and so	solid tumors including angiogenesis leads to pproach for suppressin adothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated to quence and the modifie mined the infectivity and two of the published
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β-galac specificity on human microw sequences (NGR and SPAR	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque tosidase-containing adenovirus vascular endothelial cells and s C) were able to facilitate adeno	solid tumors including angiogenesis leads to pproach for suppressin adothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines poviral vectors specific	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that ally and efficien	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated a quence and the modified mined the infectivity ar two of the published ntly transducing human
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β-galac specificity on human microw sequences (NGR and SPAR endothelial cells. These stud	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque ctosidase-containing adenovirus vascular endothelial cells and sec C) were able to facilitate adeno-	solid tumors includin angiogenesis leads to pproach for suppressi adothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines oviral vectors specific dothelial cell-targeted	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve s capsid fiber se rategy. We exan and found that ally and efficient d adenoviral vec	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated to quence and the modifie mined the infectivity and two of the published ntly transducing human ctor can be generated rate
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β-galac specificity on human microv sequences (NGR and SPAR endothelial cells. These stud simply and easily. In our fut	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of y demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque ctosidase-containing adenovirus- vascular endothelial cells and s C) were able to facilitate adence lies clearly demonstrate that en- ture studies, we will use our de	solid tumors includin angiogenesis leads to pproach for suppressin dothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines oviral vectors specific dothelial cell-targeted veloped vector to deli	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that ally and efficien d adenoviral vec ver anti-angiog	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated to quence and the modifie mined the infectivity and two of the published ntly transducing human etor can be generated ra enesis genes to tumor
Approved for Public I 13. Abstract (Maximum 200 Work Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β -galac specificity on human microw sequences (NGR and SPAR endothelial cells. These stud simply and easily. In our fut vascular structure and to eva	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque ctosidase-containing adenovirus vascular endothelial cells and sec C) were able to facilitate adeno-	solid tumors includin angiogenesis leads to pproach for suppressin dothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines oviral vectors specific dothelial cell-targeted veloped vector to deli	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that ally and efficien d adenoviral vec ver anti-angiog	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated to quence and the modifie mined the infectivity and two of the published ntly transducing human etor can be generated ra enesis genes to tumor
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β-galac specificity on human microv sequences (NGR and SPAR endothelial cells. These stud simply and easily. In our fut	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of y demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque ctosidase-containing adenovirus- vascular endothelial cells and s C) were able to facilitate adence lies clearly demonstrate that en- ture studies, we will use our de	solid tumors includin angiogenesis leads to pproach for suppressin dothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines oviral vectors specific dothelial cell-targeted veloped vector to deli	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that ally and efficien d adenoviral vec ver anti-angiog	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated a quence and the modifie mined the infectivity ar two of the published ntly transducing human etor can be generated ra enesis genes to tumor
Approved for Public I 13. Abstract (Maximum 200 Work Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β -galac specificity on human microw sequences (NGR and SPAR endothelial cells. These stud simply and easily. In our fut vascular structure and to eva	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of y demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque ctosidase-containing adenovirus- vascular endothelial cells and s C) were able to facilitate adence lies clearly demonstrate that en- ture studies, we will use our de	solid tumors includin angiogenesis leads to pproach for suppressin dothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines oviral vectors specific dothelial cell-targeted veloped vector to deli	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that ally and efficien d adenoviral vec ver anti-angiog	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated to quence and the modifie mined the infectivity and two of the published ntly transducing human etor can be generated ra enesis genes to tumor
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β -galac specificity on human microw sequences (NGR and SPAR endothelial cells. These stud simply and easily. In our fut vascular structure and to eva vivo models. 14. SUBJECT TERMS:	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque tosidase-containing adenovirus vascular endothelial cells and s C) were able to facilitate adeno- lies clearly demonstrate that en- ure studies, we will use our de aluate the efficacy of these vect	solid tumors including angiogenesis leads to pproach for suppressin adothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines oviral vectors specific dothelial cell-targeted veloped vector to delit tors to suppress breas	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that ally and efficien d adenoviral vec ver anti-angiog t tumor develop	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated to quence and the modifie mined the infectivity and two of the published ntly transducing human etor can be generated ra enesis genes to tumor
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β -galac specificity on human microw sequences (NGR and SPAR endothelial cells. These stud simply and easily. In our fut vascular structure and to eva vivo models. 14. SUBJECT TERMS:	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of y demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque ctosidase-containing adenovirus- vascular endothelial cells and s C) were able to facilitate adence lies clearly demonstrate that en- ture studies, we will use our de	solid tumors including angiogenesis leads to pproach for suppressin adothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines oviral vectors specific dothelial cell-targeted veloped vector to delit tors to suppress breas	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that ally and efficien d adenoviral vec ver anti-angiog t tumor develop	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated f quence and the modifie mined the infectivity an two of the published ntly transducing human etor can be generated ra enesis genes to tumor ment in both in vitro an
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β -galac specificity on human microw sequences (NGR and SPAR endothelial cells. These stud simply and easily. In our fut vascular structure and to eva vivo models. 14. SUBJECT TERMS: angiogenesis, gene th	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque tosidase-containing adenovirus vascular endothelial cells and s C) were able to facilitate adeno- lies clearly demonstrate that en- ture studies, we will use our de- aluate the efficacy of these vectors herapy, adenoviral vectors	solid tumors including angiogenesis leads to pproach for suppressin adothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines oviral vectors specific dothelial cell-targeted veloped vector to deli tors to suppress breas	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that ally and efficien d adenoviral vec ver anti-angiog t tumor develop	In vitro and in vivo sion. The overall goal o s. In the first year of the ctor. We incorporated f quence and the modifie mined the infectivity an two of the published ntly transducing human etor can be generated ra enesis genes to tumor ment in both in vitro an 15. NUMBER OF PAGES 7 16. PRICE CODE
Approved for Public F 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β-galace specificity on human microw sequences (NGR and SPAR endothelial cells. These stud simply and easily. In our fut vascular structure and to eva vivo models. 14. SUBJECT TERMS: angiogenesis, gene th 17. SECURITY CLASSIFICATION OF REPORT	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque tosidase-containing adenovirus vascular endothelial cells and s C) were able to facilitate adeno- ties clearly demonstrate that en- ture studies, we will use our de- aluate the efficacy of these vector herapy, adenoviral vect 18. SECURITY CLASSIFICATION OF THIS PAGE	orietary or confidential info solid tumors includin angiogenesis leads to pproach for suppressin dothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines oviral vectors specific dothelial cell-targeted veloped vector to deli tors to suppress breas	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that ally and efficien d adenoviral veo ver anti-angiog t tumor develop	In vitro and in vivo sion. The overall goal of s. In the first year of the ctor. We incorporated f quence and the modifie mined the infectivity an two of the published ntly transducing human etor can be generated ra enesis genes to tumor ment in both in vitro ar 15. NUMBER OF PAGES 7 16. PRICE CODE
Approved for Public I 13. Abstract (Maximum 200 Wor Angiogenesis is essential for experimental models clearly proposal is to develop an ad funding period, we focused previously published endoth fibers were added to β -galac specificity on human microw sequences (NGR and SPAR endothelial cells. These stud simply and easily. In our fut vascular structure and to eva vivo models. 14. SUBJECT TERMS: angiogenesis, gene th 17. SECURITY CLASSIFICATION	Release; Distribution U rds) (abstract should contain no prop r the growth and metastasis of r demonstrate that suppressing enovirus-based gene therapy ap our effort on developing the en- telial cell-specific peptide seque tosidase-containing adenoviru- vascular endothelial cells and s- C) were able to facilitate adeno- lies clearly demonstrate that en- ture studies, we will use our de- aluate the efficacy of these vector herapy, adenoviral vector 18. SECURITY CLASSIFICATION	orietary or confidential info solid tumors including angiogenesis leads to pproach for suppressin adothelial cell-targeted ences into adenovirus s with a helper-cell st everal other cell lines oviral vectors specific dothelial cell-targeted veloped vector to deli tors to suppress breas	g breast cancer. tumor suppress ng angiogenesis d adenovirus ve capsid fiber se rategy. We exan and found that ally and efficien d adenoviral veo ver anti-angiog t tumor develop	In vitro and in vivo sion. The overall goal of s. In the first year of the ctor. We incorporated f quence and the modifie mined the infectivity an two of the published ntly transducing human etor can be generated rai enesis genes to tumor ment in both in vitro an 15. NUMBER OF PAGES 7

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

Table of Contents

·

.

Cover	1
SF 298	2
Table of Contents	3
Introduction	4
Body	5
Key Research Accomplishments	6
Reportable Outcomes	6
Conclusions	6
References	6

Shuang Huang, Ph.D. DAMD17-02-1-0561


Introduction

The survival, growth and metastasis of solid tumors including breast cancer depends on the formation of new blood vessels to provide tumors with nutrients and oxygen, a process called angiogenesis. *In vitro* and *in vivo* experimental models indicate that suppressing angiogenesis can also suppress solid tumors. However, the success of this approach largely depends on whether sufficient amounts of therapeutic agents can be delivered to tumor-associated endothelial cells without causing toxic effect to other tissues/cells. Our proposal is designed to develop an endothelial cell-targeted adenoviral vector and to use the targeted vector to express high levels of anticancer therapeutic genes in the sites of angiogenic tumors specifically and efficiently.

Body

After I submitted this grant proposal, several more peptide sequences have been reported being tumor-associated endothelial cell-specific. In the first year of the funding period, we thus also tested the specificities of these peptides for endothelial cell targeting in addition to our previously proposed NGR and GSL peptides. We first synthesized oligonucleotides encoding for CGSLVRC (GSL in short) (1), CNGRCVSGCAGRC (NGR in short) (2), TCDLDNDKYIALEEWAGCFG (SPARC in short) (3), EQRLGNQWARGHLM (GRP in short) (4), and RGD peptides (2). These oligonucleotides were cloned into pDV137 plasmid. The pDV136 plasmid has two major features. 1) This plasmid contains a cloning site (Bsp E1) in HI loop of fiber gene to allow insertion; and 2) Two point mutations was introduced in the fiber gene so that the expressed is no longer able to interact with cells through the cell surface adenovirus receptor (CAR) (5). The resulted plasmids were individually transfected into 293 cells and the stable transfectants were collected. We analyzed the expression of the modified fiber and the trimerization of fiber (Fig.1) and found that the insertion of peptide sequence in the HI loop of the fiber gene did not affect fiber expression and trimerization in 293 cells. These results suggest that it is possible to use a helper-cell system to transsupply fiber to adenovirus constructs.

In the next experiment, we constructed a fiber-deleted, β -galactosidase gene containing adenoviral vector. This was done first by deleting the region encoding fiber gene from pAd.Easy-1 (Q-Biogene), and then by cloning β -galactosidase gene into pShuttle/CMV (Q-Biogene). The generated plasmids were electroporated in recombination-competent BJ5183 E.coli strain and the resulted colonies were analyzed for correct adenovirus recombination. The plasmid with correct recombination was transfected into 203 cells with various fiber constructs. The resulted adenoviral constructs are 1) fiberless Ad, 2) Ad with wild-type fiber (Ad-wt), 3) Ad with fiber containing GSL



peptide (GSL-Ad), 4) Ad with fiber containing NGR peptide (NGR-Ad), 5) Ad with fiber containing SPARC peptide (SPARC-Ad), 6) Ad with fiber containing RGD (RGD-Ad),

Shuang Huang, Ph.D. DAMD17-02-1-0561

and 7) Ad with fiber containing GRL peptides (GRL-Ad). To determine the infectivity and specificity of these viruses, HeLa and HMVCAD were infected with these viruses at 10pfu/cell (fiberless Ad was used at 100 viral particles/cell) for 48 hrs and the infection was determined by detecting counting cells with β -galoctosidase activity. As shown in Fig.2, fiberless Ad showed no infectivity to both lines suggesting fiber is required for virus infection. RGD-Ad and GRL-Ad displayed similar infectivity to Ad-wt in both lines. GSL-Ad showed better infectivity than Ad-wt in both lines. Interestingly, NRG-Ad and SPARC-Ad exhibited great infectivity to HMVCAD but showed little infectivity to HeLa cells. To further confirm the specificity of NRG-Ad and SPARC-Ad to endothelial cells, we also infected JURKAT T cells, THP1 monocytic cells, A549 lung carcinoma cells, PC3 prostate cancer cells and human foreskin fibrobast cells with these two viruses and found that all these lines were either not or only slightly infectable by NRG-Ad or SPARC-Ad (data not shown). These results suggest that we have obtained endothelial cell-specific Ad delivery vector.

Key Research Accomplishment:

• We have successfully developed a truly endothelial cell-targeted adenoviral vector.

Reportable Outcomes

The preliminary data generated from the last funding year have been used in a newly submitted grant entitled "Combating radiation resistance in prostate cancer" to the Department of Army Prostate Cancer Research Program.

Conclusions

The studies performed in the 1st year funding period demonstrate that the endothelial cell-targeted adenoviral vectors can be generated rather simply and fast. This finding is important since the major obstacle for adenovirus-based gene therapy is lack of specificity and transduction to the targeted tissues/cells.

References

- 1. Arap, W., Pasqualini, R., and Ruoslahti, E. 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. *Science* **279**:377-380.
- Mizuguchi,H., Koizumi,N., Hosono,T., Utoguchi,N., Watanabe,Y., Kay,M.A., and Hayakawa,T. 2001. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. *Gene Ther.* 8:730-735.

Shuang Huang, Ph.D. DAMD17-02-1-0561

- 3. Kupprion, C., Motamed, K., and Sage, E.H. 1998. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. *J.Biol.Chem.* **273**:29635-29640.
- 4. Gollan, T.J. and Green, M.R. 2002. Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands. *J. Virol.* **76**:3564-3569.
- 5. Nicklin,S.A., Von Seggern,D.J., Work,L.M., Pek,D.C.K., Dominiczak,A.F., Nemerow,G.R., and Baker,A.H. 2001. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generates an endothelial cell-selective adenovirus. *Mol. Therapy* 4:534-542.

Appendices

N/A